These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33464021)

  • 1. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
    Owor M; Tierney C; Ziemba L; Browning R; Moye J; Graham B; Reding C; Costello D; Norman J; Wiesner L; Hughes E; Whalen ME; Purdue L; Mmbaga BT; Kamthunzi P; Kawalazira R; Nathoo K; Bradford S; Coletti A; Aweeka F; Musoke P
    Pediatr Infect Dis J; 2021 May; 40(5):446-452. PubMed ID: 33464021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
    Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of lamivudine, zidovudine, lopinavir, and ritonavir plasma levels in HIV-positive pregnant women: Drug monitoring application to improve patient safety.
    Hernández-Pineda J; Jung-Cook HH; Katende-Kyenda NL; Galindo-Sevilla N; Domínguez-Castro M; Romo-Yañéz J; Ramírez-Ramírez A; Irles C; Figueroa-Damián R
    Medicine (Baltimore); 2020 May; 99(22):e20487. PubMed ID: 32481459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Chokephaibulkit K; Cressey TR; Capparelli E; Sirisanthana V; Muresan P; Hongsiriwon S; Ngampiyaskul C; Limwongse C; Wittawatmongkol O; Aurpibul L; Kabat B; Toye M; Smith ME; Eksaengsri A; McIntosh K; Yogev R;
    Antivir Ther; 2011; 16(8):1287-95. PubMed ID: 22155910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Third-Trimester Serum Levels of Lamivudine/Zidovudine and Lopinavir/Ritonavir in an HIV-Infected Pregnant Woman with Gastric Bypass.
    Michalik DE; Jackson-Alvarez JT; Flores R; Tolentino-Baldridge C; Batra JS
    J Int Assoc Provid AIDS Care; 2015; 14(2):116-9. PubMed ID: 25361558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
    Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines.
    Pinto JA; Capparelli EV; Warshaw M; Zimmer B; Cressey TR; Spector SA; Qin M; Smith B; Siberry GK; Mirochnick M;
    Pediatr Infect Dis J; 2018 Feb; 37(2):e29-e35. PubMed ID: 29088027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
    Sripan P; Le Coeur S; Ingsrisawang L; Cressey TR; Bouazza N; Foissac F; Ngo-Giang-Huong N; Traisathit P; Srirompotong U; Ayudhaya OP; Puangsombat A; Jungpipun J; Jittayanun K; Tréluyer JM; Jourdain G; Lallemant M; Urien S
    Antivir Ther; 2016; 21(5):435-40. PubMed ID: 26492107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
    Wang LH; Chittick GE; McDowell JA
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects.
    Huang F; Allen L; Huang DB; Moy F; Vinisko R; Nguyen T; Rowland L; MacGregor TR; Castles MA; Robinson P
    J Clin Pharm Ther; 2012 Feb; 37(1):81-8. PubMed ID: 21128991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.
    Dumond JB; Reddy YS; Troiani L; Rodriguez JF; Bridges AS; Fiscus SA; Yuen GJ; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2008 Jun; 48(2):156-62. PubMed ID: 18360288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
    Fletcher CV; Yogev R; Nachman SA; Wiznia A; Pelton S; McIntosh K; Stanley K
    Pharmacotherapy; 2004 Apr; 24(4):453-9. PubMed ID: 15098798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
    Crémieux AC; Katlama C; Gillotin C; Demarles D; Yuen GJ; Raffi F;
    Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.
    Notari S; Sergi M; Montesano C; Ivanovic J; Narciso P; Pucillo LP; Ascenzi P
    IUBMB Life; 2012 May; 64(5):443-9. PubMed ID: 22473795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.
    Bekker A; Rabie H; Salvadori N; du Toit S; Than-In-At K; Groenewald M; Andrieux-Meyer I; Kumar M; Cressey R; Nielsen J; Capparelli E; Lallemant M; Cotton MF; Cressey TR;
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):324-331. PubMed ID: 34855626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trial.
    Bekker A; Salvadori N; Rabie H; du Toit S; Than-In-At K; Groenewald M; Cressey R; Nielsen J; Capparelli EV; Lallemant M; Cotton MF; Cressey TR;
    Lancet HIV; 2024 Feb; 11(2):e86-e95. PubMed ID: 38296364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
    McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
    J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.
    Pham PA; Flexner C; Parsons T; Vasist L; Fuchs E; Carson K; Agarwala S; Barditch-Crovo P
    J Acquir Immune Defic Syndr; 2007 Jun; 45(2):201-5. PubMed ID: 17414932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.